https://www.optimumcomms.com/wp-content/uploads/2023/07/Template_Logo_300x180px-80x80Web_Logos-4.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-10-24 08:43:362023-10-24 08:44:22Astraveus awarded €10.4 million grant by the French government as part of France 2030 investment plan
https://www.optimumcomms.com/wp-content/uploads/2023/07/Template_Logo_300x180px-80x80Web_Logos-4.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-10-24 08:43:362023-10-24 08:44:22Astraveus awarded €10.4 million grant by the French government as part of France 2030 investment plan
https://www.optimumcomms.com/wp-content/uploads/2023/07/IO-Biotech.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-10-23 08:06:042023-10-23 08:06:04Encouraging Preliminary Data from a Phase 2 Trial Evaluating IO102-IO103 in Combination with Pembrolizumab for First-line Treatment of Patients with Non-small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck Presented at the European Society for Medical Oncology (ESMO) Congress
https://www.optimumcomms.com/wp-content/uploads/2023/08/Lytix_Biopharma_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-10-23 08:04:352023-10-23 08:04:35Encouraging preliminary data from Lytix Biopharma’s ATLAS-IT-05 study presented at ESMO 2023
https://www.optimumcomms.com/wp-content/uploads/2023/02/FM_Logo_300px.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-10-19 12:41:022023-10-25 12:45:39Futura Medical Launches Eroxon® in the United Arab Emirates
https://www.optimumcomms.com/wp-content/uploads/2023/08/4SC_Logo_300x180px-80x80Web_Logos-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-10-19 10:58:172023-10-19 10:58:174SC provides Q3 highlights and financial forecast
https://www.optimumcomms.com/wp-content/uploads/2023/02/Ionctura_Logo_300px-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-10-19 08:40:272023-10-19 08:40:27New Research Highlights Potential of iOnctura Strategy Combining Autotaxin and TGF-Β Inhibitors In Cancer
https://www.optimumcomms.com/wp-content/uploads/2023/08/4SC_Logo_300x180px-80x80Web_Logos-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-10-18 09:08:342023-10-18 09:08:344SC receives Orphan Drug Designation (ODD) for resminostat (Kinselby) in CTCL in the European Union
https://www.optimumcomms.com/wp-content/uploads/2023/08/Lytix_Biopharma_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-10-17 08:44:592023-10-17 08:44:59Lytix Biopharma granted up to NOK14.3m (US$1.3m) of public non-dilutive funding from ’SkatteFUNN’
https://www.optimumcomms.com/wp-content/uploads/2023/02/AMSilk_Logo_300px-2.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-10-17 08:42:422023-10-17 08:42:42AMSilk appoints Gudrun Vogtentanz as Chief Scientific Officer
https://www.optimumcomms.com/wp-content/uploads/2023/02/StormTx_Logo_300-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-10-17 08:42:252023-10-17 08:42:25STORM Therapeutics Presented Novel Pre-Clinical Data on STC-15 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
https://www.optimumcomms.com/wp-content/uploads/2023/06/Poolbeg_Logo_300x180px-80x80-4.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-10-17 08:10:272023-10-17 08:10:27Poolbeg Pharma Partners with a Nasdaq-Listed Biopharma Company on its Oral Delivery Platform
https://www.optimumcomms.com/wp-content/uploads/2023/10/splicebio-1.png
1000
1000
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-10-17 08:09:282023-10-17 08:13:09SpliceBio Enters Collaboration with Spark Therapeutics to Develop a Gene Therapy Targeting an Inherited Retinal Disease
https://www.optimumcomms.com/wp-content/uploads/2023/06/Synaffix_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-10-16 10:45:362023-10-16 10:45:36SOTIO Enters Licensing Agreement With Synaffix to Expand ADC Pipeline
https://www.optimumcomms.com/wp-content/uploads/2023/08/Lytix_Biopharma_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-10-16 08:38:252023-10-16 08:38:25Lytix Biopharma’s abstract with preliminary interim Phase II data from the ATLAS-IT-05 study is published
https://www.optimumcomms.com/wp-content/uploads/2023/02/Biocomposites_Logo_300px-2.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-10-11 08:33:552023-10-11 08:33:55Biocomposites announces new territories approved to promote STIMULAN® as an antibiotic carrier in bone and soft tissue
https://www.optimumcomms.com/wp-content/uploads/2023/06/MinervaX_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-10-11 08:06:502023-10-11 08:06:50MinervaX Raises EUR 54M in Upsized Financing to Advance the Development of its Maternal Vaccine Against Group B StreptococcusWe’d love to hear from you
For more information about Optimum Strategic Communications, please get in touch.
